The importance of neutropenia in the risk of serious infection in patients with cancer who are
receiving cytotoxic chemotherapy was first recognized nearly 30 years ago1. Since then …

''It seems more than ever likely that blood-derived stem tive capacity. 47-49 In the allogeneic
setting, mobilized blood cells have also been used instead of BM. 50 Umbilical cord cells …

The haemopoietic growth factor granulocyte colony-stimulating factor (G-CSF; filgrastim)
substantially shortens the period of severe neutropenia that follows high-dose …

As more efficient agents for stem cell mobilization are being developed, there is an urgent
need to define which patient population might benefit from these novel drugs. For a precise …

Transfusion of autologous peripheral blood stem cells (PBSCs) of good quality ensures fast
hematopoietic engraftment after myeloablative therapy with a decrease in procedure-related …

PURPOSE: To review recent advances in peripheral-blood progenitor-cell (PBPC)
transplantation in order to define the optimal cell dose required for autologous and …

To provide sufficient numbers of peripheral blood progenitor cells (PBPCs) for repetitive use
after high-dose chemotherapy, we investigated the ability of hematopoietic growth factor …

The four colony-stimulating factors (CSFs) are glycoproteins that regulate the generation
and some functions of infection-protective granulocytes and macrophages. Recombinant …

Peripheral blood mononuclear cells (PBMC) were collected after the administration of
recombinant human granulocyte colony-stimulating factor (rhG-CSF) and used as the sole …

Factors affecting mobilization and engraftment were analysed in 54 patients undergoing
transplant using autologous PBSCs mobilized with high‐dose recombinant granulocyte …